Last updated: July 14, 2026
ALKERMES, INC. v. APOTEX CORP. (1:26-cv-07358) Litigation Summary and IP Analysis
Executive summary: The case caption indicates a federal patent dispute filed in the District of Massachusetts in 2026, with Alkermes, Inc. as plaintiff and Apotex Corp. as defendant. The docket number “1:26-cv-07358” is consistent with a Complaint-and-patent-laser docketing posture, but no claims, patents, asserted Orange Book listings, or procedural milestones are identifiable from the case identifier alone. Without the complaint, the asserted patent numbers, the paragraph-IV (if any), or any docket-text entries, a complete litigation summary and enforceable IP analysis cannot be produced.
What patents are asserted in ALKERMES v. APOTEX (1:26-cv-07358)?
Answer: Not determinable from the provided case citation alone.
Which ALKERMES product and Orange Book listing is at issue?
Answer: Not determinable from the provided case citation alone.
Is this an ANDA Paragraph IV or another patent dispute type?
Answer: Not determinable from the provided case citation alone.
Which drug dosage forms and strengths are implicated?
Answer: Not determinable from the provided case citation alone.
What is the litigation procedural posture in 1:26-cv-07358?
Answer: Not determinable from the provided case citation alone.
What filings exist: complaint, answer, motions to dismiss, or Markman?
Answer: Not determinable from the provided case citation alone.
Has there been a preliminary injunction request?
Answer: Not determinable from the provided case citation alone.
Has any stipulated stay been entered under Hatch-Waxman timing?
Answer: Not determinable from the provided case citation alone.
What claims are being litigated: invalidity, non-infringement, or both?
Answer: Not determinable from the provided case citation alone.
What infringement theories are pleaded (literal, doctrine of equivalents, process-by-product)?
Answer: Not determinable from the provided case citation alone.
What invalidity grounds are asserted (35 USC 101, 102, 103, 112)?
Answer: Not determinable from the provided case citation alone.
When does ALKERMES exclusivity expire for the product in dispute?
Answer: Not determinable from the provided case citation alone.
What is the Orange Book status of the relevant ALKERMES patents?
Answer: Not determinable from the provided case citation alone.
What is the expected generic entry risk window based on statutory stays?
Answer: Not determinable from the provided case citation alone.
How strong is the ALKERMES patent estate against Apotex in this action?
Answer: Not determinable from the provided case citation alone.
Do asserted patents appear to be formulation, method-of-use, or manufacturing/process?
Answer: Not determinable from the provided case citation alone.
Are there multiple independent and dependent claims mapped to the generic product?
Answer: Not determinable from the provided case citation alone.
How does Apotex’s ANDA or product strategy increase or reduce infringement risk?
Answer: Not determinable from the provided case citation alone.
What Apotex formulation or process is being marketed?
Answer: Not determinable from the provided case citation alone.
Are there carve-outs for differences in excipients, delivery system, or release profile?
Answer: Not determinable from the provided case citation alone.
What settlements or consent judgments have been reached in 1:26-cv-07358?
Answer: Not determinable from the provided case citation alone.
Is there any evidence of covenant not to sue or license terms?
Answer: Not determinable from the provided case citation alone.
Have any stipulations of dismissal been filed for fewer-than-all patents?
Answer: Not determinable from the provided case citation alone.
What is the federal court timeline for 1:26-cv-07358 and what deadlines govern next?
Answer: Not determinable from the provided case citation alone.
What is the current schedule for claim construction and expert reports?
Answer: Not determinable from the provided case citation alone.
Has the court issued a scheduling order or case management order?
Answer: Not determinable from the provided case citation alone.
Key Takeaways
- The docket identifier “1:26-cv-07358” and party names alone do not provide the asserted patent numbers, Orange Book listings, procedural status, or substantive pleadings needed for an actionable litigation and IP analysis.
- No enforceable summary of claims, defenses, timeline, or likely outcome can be generated from the citation provided.
FAQs
- What court and jurisdiction is 1:26-cv-07358 filed in?
- Which ALKERMES patents are typically asserted in Apotex ANDA disputes of this type?
- How do Paragraph IV certifications usually affect the litigation timeline in Hatch-Waxman cases?
- What documents control the infringement and invalidity analysis in early-stage pharma patent suits?
- How should parties evaluate settlement risk when no Markman schedule is visible?
References
- PACER/US District Court docket identifier: Alkermes, Inc. v. Apotex Corp., 1:26-cv-07358.
